Lab-Grown Red Blood Cells From Stem Cells Reach Transfusion-Scale Production

Global blood supplies face persistent shortfalls, especially for patients with rare blood group phenotypes, sickle cell disease, or thalassemia who require chronic transfusions. Donor-dependent sources like cord blood and peripheral blood mononuclear cells cannot meet projected needs. Induced pluripotent stem cells (iPSCs) offer an immortal, donor-independent alternative, but converting them into fully functional, enucleated red blood cells at clinically relevant scale has remained elusive—prior systems achieved enucleation rates of only 5–25% and relied on mouse feeder layers incompatible with clinical use.

This study systematically optimized and scaled an iPSC-to-RBC differentiation platform originally described by Bernecker et al. in 2019. The key innovation is the transition from static, surface-intensive 2D monolayer culture to a fully dynamic, suspension-based 3D system. The process begins with spontaneous embryoid body (EB) formation—bypassing directed mesodermal induction—which allows a fraction of EBs to develop into hematopoietic organoids (HeOs). These HeOs create a microenvironment uniquely permissive for enucleation-competent erythroid differentiation. The team optimized EB size, shape uniformity, and HeO formation conditions, then translated each stage into dynamic suspension culture compatible with shake flasks and, ultimately, stirred bioreactors.

The optimized dynamic platform achieved 40–70% enucleation rates consistently across multiple iPSC lines—markedly superior to previous feeder-free dynamic systems (which reached only ~6%). Yield reached approximately 4,600 enucleated RBCs per input iPSC, with an estimated ~49 million iPSCs required to generate a mini-transfusion unit of ~10^10–11 cells. The resulting iRBCs expressed predominantly fetal hemoglobin (HbF, α2γ2) with minimal embryonic globin (α2ε2), displayed size and morphology consistent with fetal-wave erythropoiesis, and passed both in vitro oxygen-carrying assays and in vivo functional validation in animal models.

The system is entirely feeder-free, xeno-free, and designed to be GMP-compatible—removing a key regulatory barrier to clinical translation. The authors position this work as a bridge between proof-of-concept static culture and full bioreactor-scale manufacturing, which would be required for standard transfusion units containing ~1–2 × 10^12 RBCs. Beyond standard transfusions, the platform supports potential applications including genetic correction of hemoglobinopathies at the iPSC stage and therapeutic cargo loading of RBCs for targeted drug delivery.

Important caveats remain. The cells retain a fetal hemoglobin profile rather than fully adult HbA, though evidence suggests HbF-expressing RBCs can function as conventional transfusion products and may offer advantages for preterm infants. Full bioreactor-scale validation is not yet demonstrated, and further work is needed to confirm long-term safety, storage characteristics, and performance in allogeneic transfusion contexts before clinical trials.